ES2605945T3 - Anticuerpos de unión a Tweak - Google Patents
Anticuerpos de unión a Tweak Download PDFInfo
- Publication number
- ES2605945T3 ES2605945T3 ES11191771.2T ES11191771T ES2605945T3 ES 2605945 T3 ES2605945 T3 ES 2605945T3 ES 11191771 T ES11191771 T ES 11191771T ES 2605945 T3 ES2605945 T3 ES 2605945T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- amino acid
- acid sequence
- protein
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 8
- 239000000427 antigen Substances 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims abstract description 7
- 108091007433 antigens Proteins 0.000 claims abstract description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 5
- 230000006907 apoptotic process Effects 0.000 claims abstract description 4
- 239000000411 inducer Substances 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 102000058177 human TNFSF12 Human genes 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101000830601 Mus musculus Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68514905P | 2005-05-27 | 2005-05-27 | |
| US685149P | 2005-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2605945T3 true ES2605945T3 (es) | 2017-03-17 |
Family
ID=37482143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11191771.2T Active ES2605945T3 (es) | 2005-05-27 | 2006-05-25 | Anticuerpos de unión a Tweak |
| ES06760258.1T Active ES2507069T3 (es) | 2005-05-27 | 2006-05-25 | Anticuerpos de unión a TWEAK |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06760258.1T Active ES2507069T3 (es) | 2005-05-27 | 2006-05-25 | Anticuerpos de unión a TWEAK |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8048422B2 (enExample) |
| EP (3) | EP2460831B1 (enExample) |
| JP (4) | JP5175181B2 (enExample) |
| KR (2) | KR20080023317A (enExample) |
| CN (3) | CN102441163A (enExample) |
| AU (1) | AU2006252830B2 (enExample) |
| BR (1) | BRPI0611414B8 (enExample) |
| CA (1) | CA2609600C (enExample) |
| CY (1) | CY1118343T1 (enExample) |
| DK (2) | DK1888113T3 (enExample) |
| EA (1) | EA018255B1 (enExample) |
| ES (2) | ES2605945T3 (enExample) |
| GE (1) | GEP20115324B (enExample) |
| HU (1) | HUE030701T2 (enExample) |
| IL (1) | IL187585A (enExample) |
| IS (1) | IS8693A (enExample) |
| LT (1) | LT2460831T (enExample) |
| ME (2) | MEP35408A (enExample) |
| MX (1) | MX339015B (enExample) |
| NO (1) | NO20076607L (enExample) |
| NZ (2) | NZ564092A (enExample) |
| PL (3) | PL218791B1 (enExample) |
| PT (2) | PT1888113E (enExample) |
| RS (1) | RS55888B1 (enExample) |
| SG (1) | SG162728A1 (enExample) |
| SI (2) | SI1888113T1 (enExample) |
| UA (1) | UA96416C2 (enExample) |
| WO (1) | WO2006130374A2 (enExample) |
| ZA (1) | ZA200710765B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| HUP0105044A3 (en) | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| MXPA04009683A (es) * | 2002-04-09 | 2005-01-11 | Biogen Idec Inc | Metodos para el tratamiento de condiciones relacionadas a tweak. |
| EP1811838A4 (en) * | 2004-11-08 | 2009-07-22 | Univ Maryland | TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH |
| US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| WO2006088890A2 (en) * | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating stroke |
| DK2332408T3 (da) | 2005-02-17 | 2013-12-02 | Biogen Idec Inc | Behandling af neurologiske sygdomme |
| CA2607697C (en) * | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| US20100284933A1 (en) * | 2006-10-16 | 2010-11-11 | Biogen Idec Ma Inc. | Biomarkers of Multiple Sclerosis |
| US8685741B1 (en) * | 2007-03-07 | 2014-04-01 | Nestec S.A. | Methods for diagnosing irritable bowel syndrome |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| JP5723769B2 (ja) | 2008-06-03 | 2015-05-27 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| US8093006B2 (en) | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
| NZ621170A (en) | 2009-05-13 | 2015-08-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| SG178602A1 (en) * | 2009-09-01 | 2012-04-27 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011065940A1 (en) | 2009-11-24 | 2011-06-03 | Biogen Idec Ma Inc. | Method of supplementing culture media to prevent undesirable amino acid substitutions |
| US9068004B2 (en) | 2010-02-04 | 2015-06-30 | University Of Louisville Research Foundation, Inc. | TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration |
| RU2013103060A (ru) * | 2010-06-24 | 2014-07-27 | Эббви Инк. | Иммуноглобулины с двумя вариабельными доменами и их применение |
| SG188190A1 (en) | 2010-08-03 | 2013-04-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| BR112013007293A2 (pt) | 2010-10-05 | 2016-06-14 | Hoffmann La Roche | anticorpos contra a tweak de seres humanos e suas utilizações |
| US9120870B2 (en) | 2011-12-30 | 2015-09-01 | Abbvie Inc. | Dual specific binding proteins directed against IL-13 and IL-17 |
| EP2834273B1 (en) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| MY171664A (en) | 2012-11-01 | 2019-10-22 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| JP2016000003A (ja) * | 2013-04-19 | 2016-01-07 | アステラス製薬株式会社 | 新規抗ヒトｔｗｅａｋ抗体 |
| WO2015051234A2 (en) | 2013-10-04 | 2015-04-09 | Biogen Idec Ma Inc. | Tweak antagonists for treating lupus nephritis and muscle atrophy |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| CN112739716B (zh) | 2018-05-07 | 2025-05-27 | 展马博联合股份有限公司 | 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法 |
| US12220570B2 (en) | 2018-10-05 | 2025-02-11 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| AU2019371814A1 (en) | 2018-10-29 | 2021-06-17 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| JP7415939B2 (ja) * | 2018-10-31 | 2024-01-17 | アステラス製薬株式会社 | 抗ヒトＦｎ１４抗体 |
| CN112778372B (zh) * | 2019-11-11 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用 |
| TW202302648A (zh) * | 2021-03-12 | 2023-01-16 | 美商健生生物科技公司 | Cd79b抗體於自體免疫治療應用之用途 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AT396939B (de) * | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
| ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
| WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US7129061B1 (en) | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| SI0956351T1 (sl) | 1996-08-07 | 2006-02-28 | Biogen Idec Inc | Ligand, sosroden faktorju tumorske nekroze |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| CA2280231A1 (en) | 1997-02-12 | 1998-08-13 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| EP1967587A1 (en) | 1997-10-10 | 2008-09-10 | Genentech, Inc. | APO-3 Ligand |
| NZ511488A (en) * | 1998-10-16 | 2003-10-31 | Immunex Corp | Inhibitors of platelet activation and recruitment comprising an Ala residue and heterologous peptides capable of forming a stable secondary structure attached to a CD39 polypeptide |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| HUP0105044A3 (en) * | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| US7309687B1 (en) * | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| JP5148795B2 (ja) | 1999-12-20 | 2013-02-20 | イミュネックス・コーポレーション | Ｔｗｅａｋ受容体 |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
| NZ522741A (en) | 2000-05-08 | 2005-06-24 | Biogen Idec Inc | Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor, such as fibroblast growth factor and VEGF |
| US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| EP1317283B1 (en) | 2000-09-14 | 2011-07-06 | Biogen Idec MA Inc. | Tweak receptor agonists as anti-angiogenic agents |
| DE60205923T2 (de) | 2001-09-27 | 2006-05-18 | Matsushita Electric Industrial Co., Ltd., Kadoma | Übertragungsverfahren, sendegerät und empfangsgerät |
| MXPA04009683A (es) | 2002-04-09 | 2005-01-11 | Biogen Idec Inc | Metodos para el tratamiento de condiciones relacionadas a tweak. |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| WO2005010045A1 (en) | 2003-07-24 | 2005-02-03 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
| EP1566636A1 (en) | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
| EP1811838A4 (en) | 2004-11-08 | 2009-07-22 | Univ Maryland | TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH |
| US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| WO2006088890A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating stroke |
| DK2332408T3 (da) | 2005-02-17 | 2013-12-02 | Biogen Idec Inc | Behandling af neurologiske sygdomme |
| EP1853312B1 (en) | 2005-03-07 | 2014-12-10 | Genentech, Inc. | Methods and compositions for modulating tweak and fn14 activity |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006130429A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| US20100284933A1 (en) | 2006-10-16 | 2010-11-11 | Biogen Idec Ma Inc. | Biomarkers of Multiple Sclerosis |
-
2006
- 2006-05-25 CN CN2011103581313A patent/CN102441163A/zh active Pending
- 2006-05-25 ES ES11191771.2T patent/ES2605945T3/es active Active
- 2006-05-25 EP EP11191771.2A patent/EP2460831B1/en active Active
- 2006-05-25 SI SI200631822T patent/SI1888113T1/sl unknown
- 2006-05-25 ME MEP-354/08A patent/MEP35408A/xx unknown
- 2006-05-25 CN CN2006800275811A patent/CN101247830B/zh not_active Expired - Fee Related
- 2006-05-25 LT LTEP11191771.2T patent/LT2460831T/lt unknown
- 2006-05-25 JP JP2008513580A patent/JP5175181B2/ja not_active Expired - Fee Related
- 2006-05-25 UA UAA200714838A patent/UA96416C2/uk unknown
- 2006-05-25 KR KR1020077030638A patent/KR20080023317A/ko not_active Ceased
- 2006-05-25 GE GEAP200610459A patent/GEP20115324B/en unknown
- 2006-05-25 MX MX2013013851A patent/MX339015B/es unknown
- 2006-05-25 RS RS20070462A patent/RS55888B1/sr unknown
- 2006-05-25 CA CA2609600A patent/CA2609600C/en not_active Expired - Fee Related
- 2006-05-25 AU AU2006252830A patent/AU2006252830B2/en not_active Ceased
- 2006-05-25 PL PL384684A patent/PL218791B1/pl unknown
- 2006-05-25 PL PL06760258T patent/PL1888113T3/pl unknown
- 2006-05-25 SI SI200632111A patent/SI2460831T1/sl unknown
- 2006-05-25 NZ NZ564092A patent/NZ564092A/en not_active IP Right Cessation
- 2006-05-25 NZ NZ583636A patent/NZ583636A/en not_active IP Right Cessation
- 2006-05-25 BR BRPI0611414A patent/BRPI0611414B8/pt not_active IP Right Cessation
- 2006-05-25 SG SG201003724-0A patent/SG162728A1/en unknown
- 2006-05-25 ME MEP-2008-354A patent/ME00261B/me unknown
- 2006-05-25 EP EP06760258.1A patent/EP1888113B1/en not_active Not-in-force
- 2006-05-25 ES ES06760258.1T patent/ES2507069T3/es active Active
- 2006-05-25 HU HUE11191771A patent/HUE030701T2/hu unknown
- 2006-05-25 PT PT67602581T patent/PT1888113E/pt unknown
- 2006-05-25 DK DK06760258.1T patent/DK1888113T3/da active
- 2006-05-25 EA EA200702643A patent/EA018255B1/ru not_active IP Right Cessation
- 2006-05-25 PL PL11191771T patent/PL2460831T3/pl unknown
- 2006-05-25 WO PCT/US2006/019706 patent/WO2006130374A2/en not_active Ceased
- 2006-05-25 PT PT111917712T patent/PT2460831T/pt unknown
- 2006-05-25 KR KR1020137032481A patent/KR101679468B1/ko not_active Expired - Fee Related
- 2006-05-25 EP EP11191813A patent/EP2460832A3/en not_active Withdrawn
- 2006-05-25 DK DK11191771.2T patent/DK2460831T3/en active
- 2006-05-25 CN CN201310054744.7A patent/CN103242447B/zh not_active Expired - Fee Related
-
2007
- 2007-11-22 IL IL187585A patent/IL187585A/en active IP Right Grant
- 2007-11-26 US US11/944,709 patent/US8048422B2/en not_active Expired - Fee Related
- 2007-11-29 IS IS8693A patent/IS8693A/is unknown
- 2007-12-10 ZA ZA200710765A patent/ZA200710765B/xx unknown
- 2007-12-27 NO NO20076607A patent/NO20076607L/no not_active Application Discontinuation
-
2011
- 2011-09-09 US US13/228,784 patent/US20120009178A1/en not_active Abandoned
-
2012
- 2012-11-22 JP JP2012256386A patent/JP2013040210A/ja not_active Withdrawn
-
2014
- 2014-08-25 JP JP2014170135A patent/JP2014221837A/ja not_active Withdrawn
-
2016
- 2016-10-31 JP JP2016212746A patent/JP6234535B2/ja not_active Expired - Fee Related
- 2016-12-14 CY CY20161101291T patent/CY1118343T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2605945T3 (es) | Anticuerpos de unión a Tweak | |
| US11390676B2 (en) | Anti-LAG-3 antibodies and compositions | |
| ES2593754T3 (es) | Anticuerpos anti-IL-23 | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2016510319A (ja) | 多価結合タンパク質組成物 | |
| ES2818074T3 (es) | Agente de unión a IL-17A y sus usos | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2020514277A5 (enExample) | ||
| JP2013507929A (ja) | Ｉｌ−１結合蛋白質 | |
| JP2019527194A5 (enExample) | ||
| RU2008132968A (ru) | Антитела к рецептору тимусного стромального лимфопоэтина | |
| HRP20220405T1 (hr) | Protutijela protiv ngf i njihova upotreba | |
| KR20180027566A (ko) | 타우 결합 항체 | |
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| SI2796466T1 (en) | Molecules of Humanized Specifics Specifiable for IL-31 | |
| KR20120089659A (ko) | 치료용 ｄｌｌ4 결합 단백질 | |
| RU2011121419A (ru) | Иммуноглобулины | |
| KR20190028716A (ko) | Pd-l1-특이적 항체 및 이를 사용하는 방법 | |
| JP2012532851A5 (enExample) | ||
| WO2020007240A1 (zh) | 一种双特异性抗体及其用途 | |
| TR201907261T4 (tr) | DKK-1 antikorları. | |
| HRP20210892T1 (hr) | Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv | |
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина |